IBD Unclassified

IBD unclassified · indeterminate colitis

Coming soon

When your diagnosis falls between Crohn’s and colitis

IBD unclassified (IBD-U) is a real diagnosis for people with inflammatory bowel disease whose biopsy and imaging features don’t clearly distinguish Crohn’s disease from ulcerative colitis — and that uncertainty deserves real answers.

Questions or collaboration? [email protected]

← Back to the IBDology network

What is IBD unclassified?

IBD unclassified (IBD-U, also called indeterminate colitis) is the diagnosis when biopsies and imaging show clear inflammation of the colon, but the pattern doesn’t fit neatly into either Crohn’s disease or ulcerative colitis. It accounts for roughly 5–15% of IBD diagnoses and is not a “waiting diagnosis” — many people with IBD-U remain IBD-U for their entire course.

Why IBD-U matters

IBD Unclassified is part of the Holubar Lab IBDology network, bridging IBDology (the hub), Crohnsology (Crohn’s disease), and Pouchology (pouch surgery outcomes).

Support & community: Crohn’s & Colitis Foundation · Cleveland Clinic IBD · IBDology.org

Frequently Asked Questions

What is IBD unclassified (IBDU)?

IBD unclassified (IBDU), also called indeterminate colitis (IC), is a diagnosis assigned when colonic inflammatory bowel disease has definitive histological and endoscopic features of IBD but cannot be definitively classified as ulcerative colitis or Crohn's disease after thorough pathological review of surgical specimens. IBDU accounts for approximately 5–15% of IBD cases. It is a working diagnosis — many patients eventually evolve to a definitive UC or CD diagnosis over time.

How is IBDU different from ulcerative colitis and Crohn's disease?

Ulcerative colitis (UC) causes continuous mucosal inflammation limited to the colon, while Crohn's disease (CD) involves transmural, often segmental inflammation that can affect the entire GI tract. IBDU shares features of both: it is limited to the colon (like UC) but may show transmural inflammation, focal areas of relative rectal sparing, or fissuring ulcers (more typical of CD). The distinction matters because surgical options and long-term outcomes differ between UC and CD.

Can patients with IBDU have pouch surgery (IPAA)?

Yes, ileal pouch-anal anastomosis (IPAA) is offered to IBDU patients, though outcomes are slightly less favorable than for definitive UC. The key concern is that a proportion of IBDU patients may harbor occult Crohn's disease, which adversely affects pouch function and increases complication rates (pouchitis, fistula, pouch failure). Careful preoperative evaluation — including capsule endoscopy to exclude small bowel disease — is essential before proceeding with restorative proctocolectomy in IBDU.

How is IBDU diagnosed?

The diagnosis of IBDU is made after colonoscopy with biopsy, cross-sectional imaging (CT or MRI enterography) to evaluate the small bowel, and — if colectomy has been performed — review of the surgical pathology specimen. Serologic markers (ANCA, ASCA, anti-OmpC, anti-Cbir1) and fecal calprotectin may support classification but are not definitive. A multidisciplinary review by gastroenterology and pathology is recommended before labeling a patient as IBDU.

What are the surgical options for IBDU?

The surgical approach for medically refractory IBDU mirrors that for UC: total abdominal colectomy with end ileostomy (the safest first step in acutely ill patients), followed by completion proctectomy and either IPAA (restorative) or permanent end ileostomy. Because of the diagnostic uncertainty, some surgeons prefer a staged approach — colectomy first, then definitive pathology review — before committing to IPAA. Patients should be counseled that subsequent reclassification as Crohn's disease could affect long-term pouch function.

Does an IBDU diagnosis change over time?

Yes. IBDU is considered a provisional diagnosis. Longitudinal data show that 30–50% of patients initially classified as IBDU are eventually reclassified as UC or CD within 5–10 years of follow-up, as new clinical, endoscopic, or histologic information emerges. This is why ongoing gastroenterologic surveillance and communication between the patient's IBD physician and surgeon remain important throughout the disease course.